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Behçet disease (BD) is an inflammatory systemic disease with a fluctuating course,
which can affect the skin, eyes, central nervous system,musculoskeletal, gastrointestinal,
and vascular systems. No laboratory tests are currently available for the diagnosis of
BD and monitoring disease activity. Moreover there is a lack of knowledge on BD
pathogenesis. This study focused on circulating Natural Killer (NK), NKT and T cells
evaluated as CD3neg CD56pos, CD3pos CD56pos, and CD3pos CD56neg. Peripheral
blood mononuclear cells (PBMCs) were collected from 38 BD patients and 20 healthy
controls (HC). The frequencies of NK, NKT, and T cells expressing CD16, CD69, NKG2D,
Nkp30, Nkp46, and NKG2A were assessed by flow cytometry. Cytotoxic potential of
NK cells was evaluated by flow cytometry as the percentage of cells expressing the
degranulation marker CD107a after incubation with K562 cells. The levels of 27 cytokines
were determined in plasma with a multiplex bead-based assay. Higher percentages of
NK, NKT, and T cells expressing NKG2D were detected in PBMCs of BD patients than
HC. ROC curve analysis showed that the evaluation of NKG2Dpos NK, NKT, and T cell
percentages discriminated between BD patients and HC. Moreover, there was a positive
correlation between the BD Current Activity Form (BDCAF) scores and the frequencies
of NKG2Dpos NK and NKT cells. A higher frequency of NK cells expressing CD107a
was induced in PBMCs from BD patients than HC after incubation with K562 cells.
Concentrations of IL-5, IL-6, IL-10, IL-13, IP-10, and MIP-1β were higher in plasma of BD
patients than HC. Monitoring the frequencies of NKG2Dpos lymphocytes could help the
clinicians in BD patients management. In addition, the increased expression of NKG2D
in BD patients is likely involved in disease pathogenesis.
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INTRODUCTION
Behçet disease (BD) is a rare, systemic, inflammatory
chronic disease with multiorgan damage and various clinical
manifestations and characterized by alternation of active
and remitting phases. BD can affect mucocutaneous, ocular,
musculoskeletal, nervous, vascular, gastrointestinal, and cardiac
compartments (1). Both genders are affected and the onset is
more common in the third decade of life, but in young males
the course of disease is more severe (1). Etiopathogenesis is
still unknown but genetic and environmental factors are likely
implicated in the onset of the disease. Despite HLA-B51 and
some gene polymorphisms have been associated with BD (2, 3),
the diagnosis is based on a combination of clinical symptoms
and signs. Currently no laboratory assays or imaging approaches
are available to support the clinical diagnosis. The classification
criteria, introduced in 1990 and successively reviewed in 2006,
are still a matter of discussion (4), however they help the
physicians in identifying the patients with this condition. The
BD Current Activity Form (BDCAF) is the most widely used
index to assess disease activity in BD (5). BDCAF was developed
in 1999 (6) and it scores the presence or absence of clinical
features (oral ulcers, genital ulcers, skin lesions, etc.) which were
present during the 4 weeks prior to the day of assessment.
Natural killer (NK) cells are cytotoxic lymphocytes able to
recognize cells lacking self-MHC class I molecules or cells which
display changes in the surface self-molecules. Upon activation,
NK cells release cytotoxic granules which contain perforin and
granzymes, leading to the destruction of cellular membrane
of target cells and subsequently apoptosis (7). Natural killer
T (NKT) cells are a lymphocyte subpopulation which express
surface molecules characteristic of NK and T cells. Like NK cells,
activated NKT cells release in the extracellular compartment pro-
and anti-inflammatory cytokines/chemokines with the function
of regulating the immune response (8). The activation of NK
and NKT cells derives from the balance of signals coming from
activatory and inhibitory receptors (9, 10). There are some
evidences about the possible involvement of NK and NKT cells
in the pathogenesis of BD, but there is a discrepancy in the
data. An increased frequency of circulating NK and NKT cells
in BD patients compared to healthy controls (HC) has been
reported (11–14). Conversely, other authors have reported a
decreased frequency of circulating NK and NKT cells in BD
patients compared to HC (15, 16).
This study aimed to identify a specific profile of circulating
NK, NKT, and T cells able to discriminate between BD patients
andHC, investigating the phenotypic characteristics of such cells,
the cytotoxic potential of NK cells and quantifying 27 cytokines
in plasma. The analysis of peripheral blood NK, NKT and T cells
could increase the knowledge about the molecular mechanisms
involved in the pathogenesis of BD.
MATERIALS AND METHODS
Cohorts of Patients and Healthy Controls
A cohort of 38 BD patients was enrolled at the Azienda Unità
Sanitaria Locale-IRCCS, Arcispedale Santa Maria Nuova, Reggio
Emilia, Italy. All patients satisfied the International Study Group
for Behçet disease criteria (ISGB 1990). For the evaluation of
the disease activity, the BDCAF 2006 was administered to the
patients during the rheumatologic visit. The median age was 40
years (InterQuartile Range; IQR: 29–50) and gender distribution
was: 55% male (21/38) and 45% female (17/38). 74% (28/38)
of BD patients were receiving therapies. The characteristics of
each BD patient and the type of therapy are summarized in
Table S1. 20 age-matched HC were recruited as reference. The
median age was 40 (IQR: 33–58) and gender distribution was:
40% (8/20) male and 60% (12/20) female. They did not have
any autoimmune diseases, infections, and cancers at the time of
blood withdrawal. The median age and gender distribution were
similar between the two cohorts. The study was approved by the
Local Ethics Committee (Reggio Emilia, Italy, protocol number
2015/0024354) in compliance with the Declaration of Helsinki
and written informed consent was obtained from all patients and
healthy controls.
Biological Sample Collection
18mL of venous blood were collected from each subject
into EDTA coated tubes. Peripheral blood mononuclear cells
(PBMCs) were isolated by histopaque-1077 density gradient
centrifugation (Sigma-Aldrich) and stored frozen in liquid
nitrogen in 90% heat inactivated fetal bovine serum (FBS, Gibco,
ThermoFisher) 10% dimethyl sulfoxide (DMSO, Sigma-Aldrich)
until use. Plasma was collected and stored at−80◦C until use.
Flow Cytometry
PBMCs were thawed and counted with a Fuchs-Rosenthal
hemocytometer. The viability of thawed PBMCs was evaluated
by Trypan Blue assay. 5 × 105 cells were suspended in 100
µL Phosphate-Buffered Saline (PBS, Euroclone) + 1% FBS and
stained for 25min at 4◦C with the following antibodies: PerCP
mouse anti-human CD3 (clone BW264/56), PE anti-human
CD56 (clone REA196), FITC anti-human CD16 (clone REA423),
PE-Vio770Tm mouse anti-human CD69 (clone FN50), and APC
mouse anti-human NKG2D (clone BAT221). Alternatively, 5 ×
105 cells/100 µL PBS + 1% FBS were stained for 25min at
4◦C with PerCP mouse anti-human CD3 (clone BW264/56), PE
anti-human CD56 (clone REA196), PE-Vio770Tm anti-human
NKG2A (clone REA110), APC mouse anti-human Nkp30 (clone
AF29-4D12), VioBrightTm FITC mouse anti-human Nkp46
(clone 9E2) antibodies. All antibodies were purchased from
Miltenyi Biotec and used as suggested by the manufacturer.
After washing, PBMCs were suspended in PBS + 1% FBS
and acquired with the FACSCanto II flow cytometer (BD
Biosciences), equipped with two lasers for excitation at 488 and
633 nm. Data were analyzed with FACSDiva 8.0.1 software. At
least 60,000 lymphocytes were acquired. Gates were defined using
fluorescence minus one (FMO) controls (Figure S1). To be sure
that freezing and defrost process did not differentially altered
the percentages of NK, NKT, and T cells and the expression of
the surface markers, results obtained with fresh PBMCs were
compared with those obtained with thawed PBMCs from BD
patients vs. HC. The freezing/defrost process did not modify
the percentages of NK, NKT, and T lymphocytes and the
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percentages of cells positive for the investigated surface markers
with the exception of a reduction >10% in the frequencies of
CD69pos NK, NKG2Apos T, Nkp46pos NK cells in all the samples.
Since such reductions were similar in thawed PBMCs from BD
patients and HC (Table S2), analyses were performed on thawed
PBMCs.
Cell Lines
K562 cell line, a human erythroleukemic cell line which does not
express MHC class I molecules, was provided by Dr. Alessandro
Zerbini from the Azienda Ospedaliero-Universitaria of Parma,
Italy and maintained in RPMI 1640 (Gibco, ThermoFisher)
supplemented with 10% FBS, 100 U/mL penicillin (Euroclone),
and 100µg/mL streptomycin sulfate (Euroclone) at 37◦C, 5%
CO2.
Degranulation Assay
PBMCs were thawed, counted with a Fuchs-Rosenthal
hemocytometer and suspended at a density of 2 × 106
cell/mL in RPMI 1640 supplemented with 10% FBS, 100 U/mL
penicillin and 100µg/mL streptomycin sulfate. After overnight
incubation at 37◦C, 5% CO2 with or without 1 ng/mL IL-15
(Miltenyi Biotec), 5 × 105 PBMCs were incubated with K562
target cells, at an effector to target ratio of 5:1, in presence of
mouse anti-human CD107a APC-conjugate antibody (clone
H4A3, Miltenyi Biotec) for 1 h at 37◦C, 5% CO2. Then, 10µg/mL
brefeldin A (Sigma-Aldrich) and 6µg/mL monensin (Sigma-
Aldrich) were added to the cells and incubation was carried out
for additional 3 h at 37◦C, 5% CO2. Cells were first stained with
100 µL Live/Dead Fixable Dead Cell Stain near-IR-fluorescent
reactive dye (Life Technologies) at 0.1% in PBS for 15min at
room temperature and then with the antibodies against the
surface antigens CD3 and CD56 diluted in 100 µL of PBS +
1% FBS for 25 min at 4◦C. After washing, cells were suspended
in PBS + 1% FBS and acquired with the FACSCanto II flow
cytometer. Gates were defined using FMO controls (Figure S2).
To be sure that freezing and defrost process did not differentially
altered the percentage of CD107a NK cells, results obtained with
fresh PBMCs were compared with those obtained with thawed
PBMCs from BD patients vs. HC. The freezing/defrost process
reduced more than 10% the frequencies of CD107apos NK cells
in thawed PBMCs in all the samples. Since such reductions were
similar in thawed PBMCs from BD patients and HC (Table S2),
analyses were performed on thawed PBMCs.
Cytokine Assay
Concentrations of IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-
8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17A, Eotaxin, Basic
FGF, G-CSF, GM-CSF, INF-γ, IP-10, MCP-1, MIP-1α, MIP-
1β, PDGF-BB, RANTES, TNF-α, and VEGF were determined
in plasma of BD patients and HC by the Bio-Plex Pro
Human Cytokine Group I Panel, 27-Plex (Biorad) following the
manufacturer’s instruction. Plasma was diluted four-fold in Bio-
Plex Sample Diluent as recommended. Data were obtained with
the MAGPIXTM Multiplex Reader instrument and Bio-Plexr
ManagerTM software. Values extrapolated from the standard
curve were considered not reliable and a concentration = 0.01
pg/mL was arbitrary assigned (Table S3 for the lower limits of
detection).
Statistical Analysis
Statistical analyses were performed with GraphPad Prism 7
software. For comparisons between two groups non-parametric
Mann-Whitney U test was used for quantitative variables, while
Fisher’s exact test was used for qualitative variables. To adjust
for multiple testing, in addition to individual p-values, we used
the Benjamini and Hochberg method, to control for a false-
discovery-rate <10%. Spearman test was used for correlations
between two variables and receiver operating characteristic
(ROC) curve was used to assess the performance of a binary
classifier system. The performances of the combination of ROC
curves were evaluated via logistic regression and Area Under
the Curve (AUC) estimation (with 95% confidence interval).
AUCs were then compared with z test using R 3.5.0. P < 0.05
(two-tailed) were considered statistically significant.
RESULTS
Circulating NK, NKT, and T Cells
Percentages in BD Patients and HC
Gating strategy for identification of lymphocyte subsets is shown
in Figure S1. In the lymphocyte gate NK, NKT, and T cells
were defined as CD3neg CD56pos, CD3pos CD56pos, and CD3pos
CD56neg respectively. The median viability of thawed PBMCs
were similar between BD patients and HC: 96.1% (IQR: 92.8–
97.2%) vs. 96.0% (IQR: 93.9–97.1%). No differences were found
in the percentages of NK, NKT, T cells in peripheral blood
between BD patients and HC (Figure 1A). The classification
of BD patients based on BDCAF scores did not reveal any
correlations with the percentages of NK, NKT, and T cells
(Figure 1B). Moreover, we did not find any differences in the
percentages of NK, NKT, and T cells if BD patients were classified
according to the presence (n= 28) or absence (n= 10) of therapy
(Figure 1C). The percentages of CD56bright NK cells were similar
between BD patients and HC (data not shown).
Surface Markers of NK and NKT Cells in
BD Patients and HC
In order to characterize the immunophenotype of circulating
lymphocytes in BD patients, the frequencies of cells expressing
the activatory markers CD69, CD16, NKG2D, Nkp30, Nkp46
and the inhibitory marker NKG2A were analyzed within each
lymphocyte subset compared to HC (refer to Figure S1 for
the gating strategy). We observed a significant increase in
the frequencies of NKG2Dpos NK, NKT, and T cells in BD
patients with respect to HC (Figure 2A). In particular, the
median frequency of NKG2Dpos NK cells was 70.6% (IQR:
59.5–81.2%) in BD vs. 55.4% (IQR: 44.8–63.1%) in HC; while
the median frequency of NKG2Dpos NKT cells was 72.3%
(IQR: 64.1–78.8%) in BD vs. 58% (IQR: 49.8–68.8%) in HC
and the median frequency of NKG2Dpos T cells was 29.5%
(IQR: 25.4–37.4%) in BD vs. 22.2% (IQR: 17.4–27.7%) in
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FIGURE 1 | PBMC subsets in BD patients and HC. (A) Dot plot visualization of the percentages of NK, NKT, and T cells in the lymphocyte gate by flow cytometry in
PBMCs from BD patients ( ) and HC (). Horizontal lines show the median ± InterQuartile Range (IQR). Data were analyzed by Mann-Whitney U test. (B) Dot plot
visualization of the correlation between the frequencies of NK, NKT, and T cells and BDCAF scores for each BD patient. Data were analyzed by Spearman’s correlation
test (n = 38). (C) Dot plot visualization of the percentages of NK, NKT and T cells determined by flow cytometry in PBMCs from BD patients classified according to
presence (N) or absence (◦) of therapy. Horizontal lines show the median ± IQR. Data were analyzed by Mann-Whitney U test.
HC. After adjustment for multiple testing, the increase in the
frequencies of NKG2Dpos NK, NKT, and T cells in BD patients
remained statistically significant.
ROC curve analysis showed that the evaluation of the
percentage of NKG2Dpos cells in the lymphocyte gate allowed
to discriminate between BD patients and HC with low-medium
sensitivity but high specificity (Figure 2B for details). No
significant differences in AUCs were observed when the ROC
curve based on the percentage of NKG2Dpos NK cells was
compared with the ROC curves combining the percentages of
NKG2Dpos NK+T cells (P = 0.627) or NKG2Dpos NK+T+NKT
cells (P = 0.547) (Figure S3).
The classification of BD patients based on BDCAF scores
revealed a direct correlation with the frequencies of NKG2Dpos
NK and NKT cells, while no correlation was observed with the
frequency of NKG2Dpos T cells (Figure 2C). The subsequent
division of patients with BDCAF = 0 (n = 6) and BDCAF
≥ 3 (n = 32) showed a significant higher frequencies of
NKG2Dpos NK, NKT, and T cells in patients with BDCAF
≥ 3 in comparison with patients with BDCAF = 0 and HC
(Figure 2D). The frequencies of NKG2Dpos NK, NKT, and T cells
of BD patients with BDCAF = 0 were similar to the frequencies
detected in HC (Figure 2D). Instead, the classification of patients
according to the presence/absence of therapy did not show any
differences in the percentages of NKG2Dpos NK, NKT and T cells
(Figure 3).
Concerning the frequencies of NK, NKT, and T cells positive
for the other inhibitory and activatory surface markers, no
differences were found between BD patients and HC (Figure 4).
Neither the classification of BD patients based on BDCAF
scores nor the classification according to the presence/absence of
therapy showed any differences in the percentages of NK, NKT,
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FIGURE 2 | NKG2D expression in lymphocytes from BD patients and HC. (A) Dot plot visualization of the percentages of NKG2Dpos cells in the NK, NKT, and T
lymphocyte gate determined by flow cytometry in PBMCs from BD patients ( ) and HC (). Horizontal lines show the median ± IQR. Data were analyzed by
Mann-Whitney U test. (B) ROC curve analysis of the percentages of NKG2Dpos cells in NK, NKT, and T lymphocyte gates. AUC, Area Under the Curve; CI,
Confidence Interval; Thr, Threshold; Se, Sensitivity; Sp, Specificity. (C) Dot plot visualization of the correlation between the frequencies of NKG2Dpos NK, NKT, and T
cells and BDCAF scores for each BD patient. Data were analyzed by Spearman’s correlation test (n = 38). (D) Box plot visualization of the frequencies of NKG2Dpos
NK, NKT, and T cells in BD patients with BDCAF = 0 vs. BDCAF ≥ 3 and HC. Data were analyzed by Mann-Whitney U test.
and T cells expressing the CD69, CD16, Nkp30, Nkp46, and
NKG2A surface markers (Figure S4, S5).
Cytotoxic Potential of NK Cells
To study the cytotoxic potential of NK cells, PBMCs of BD
patients and HC were stimulated through contact with K562
cells, which do not express MHC-I, followed by the analysis
of the expression of the CD107a degranulation marker. The
stimulus with K562 cells is specific for NK cells and it does
not activate the cytotoxic potential of NKT and T cells. A
significant higher frequency of CD107apos NK cells was induced
in BD patients compared to HC: 13.43% (IQR: 8.09–15.95%) vs.
9.54% (IQR: 6–12.33%), P = 0.0314 (Figure 5A). In particular, a
bimodal distribution appeared in the cohort of BD patients with 5
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FIGURE 3 | NKG2D expression in lymphocytes of BD patients classified according to the therapy. Dot plot visualization of the percentages of NKG2Dpos cells in the
NK, NKT, and T lymphocyte gates determined by flow cytometry in PBMCs from BD patients classified according to presence (N) or absence (◦) of therapy. Horizontal
lines show the median ± IQR. Data were analyzed by Mann-Whitney U test.
patients showing a higher frequency of CD107apos NK cells. We
were not able to find any commonalities in such subjects (e.g.,
presence/absence of therapy, type of therapy, organ involvement,
disease activity, sex, age, HLA-B51 status). Further stimulation
of PBMCs with IL-15 increased the percentages of CD107apos
cells, but no differences were found between BD patients and
HC (Figure 5B). Neither the classification of BD patients based
on the BDCAF scores nor the classification according to the
presence/absence of therapy revealed any differences in the
cytotoxic potential of NK cells (Figure 6).
Cytokine Plasmatic Levels in BD Patients
and HC
Multiplex analysis of 27 cytokines using plasma samples revealed
a significantly higher concentration of IL-4, IL-5, IL-6, IL-10,
IL-13, IL-17A, IP-10, MCP-1, and MIP1β in BD patients in
comparison to HC (Table 1). After adjustment for multiple
testing, the increase of IL-5, IL-6, IL-10, IL-13, IP-10, and MIP1β
in plasma of BD patients remained statistically significant. No
differences were found in BD patients classified on BDCAF scores
(Table S4), while the classification according to presence/absence
of therapy revealed a higher concentration of IP-10 in plasma
of BD patients without therapy in comparison to patients under
therapy: 835.5 pg/mL (IQR: 570.7–1398 pg/mL) vs. 446.3 pg/mL
(IQR: 297.6–676.1 pg/mL), P = 0.0023. The concentration of
IP-10 in plasma of BD patients with therapy was similar to the
concentration detected in HC (319 pg/mL; IQR: 310.7–484.1).
Instead, the concentration of IP-10 in plasma of BD patients
without therapy was significantly higher than that of HC (P
< 0.0001). Some cytokines were detected only in a fraction of
subjects and the differences of frequencies of detection were
statistically significant between BD patients and HC in the case of
IL-6, IL-10, and IL-13 (Table 1). In particular, IL-6 was detected
in 15/38 (39%) of BD patients and 2/20 (10%) of HC, IL-10 was
detected in 19/38 (50%) of BD patients, and 4/20 (20%) of HC,
while IL-13 was detected in 38/38 (100%) of BD patients and
15/20 (75%) of HC.
DISCUSSION
The present work contributes to expand the knowledge about
the mechanisms underlying Behçet disease. For the first time,
we reported an increased frequencies of circulating NK, NKT,
and T cells positive for the activatory surface marker NKG2D
in BD patients compared to HC. Differently from other
authors, we did not find any differences in the frequencies
of circulating NK, NKT, and T lymphocytes in BD patients
compared to HC (12–16). The clinical heterogeneity of the
patients (e.g., regarding pre-existing therapy, disease activity
and pattern of organ involvement), different ethnicity and
different surface markers used for lymphocyte identification
could explain the discrepancy of the results obtained so far in BD
patients.
NKG2D is a homodimeric C-type lectin-like activating
receptor that is expressed on almost all NK and CD8pos T cells
andwith less frequency on the surface of NKT andCD4pos T cells.
NKG2D acts as a sensor for recognition of induced-self antigens
in cells infected by pathogens, transformed or stressed cells (17).
In humans, 8 different ligands able to bind the NKG2D receptor
with different affinity are known: MHC class I chain-related
protein A (MICA) and protein B (MICB) and 6 HCMV UL16
binding proteins. Consequent the binding of ligands, NKG2D
receptor can initiate an intracellular signal cascade that leads to
NK andNKT activation (18). Conversely in T cells the function of
NKG2D receptor is different acting as a co-stimulatory molecule
enhancing T-cell receptor activation (TCR) and T cells functions
(19). In human beings some polymorphisms in MICA gene
have been documented. In particular, in patients with BD the
polymorphisms in MICA gene: ∗009 and TM A6 have been
found more frequently and are in linkage disequilibrium with
HLA-B51 (20, 21). There is not a definitive consensus on
whether polymorphisms in MICA gene or HLA-B51 or both
have a causal role in the onset of BD. The consequences of
MICA polymorphism at protein level (e.g., protein turnover,
conformation, interaction with ligands) are still under debate and
need to be uncovered to understand their possible involvement in
disease pathogenesis.
NKG2D expression has been discovered as altered in different
autoimmune diseases. In rheumatoid arthritis an increased
percentage of NKG2Dpos CD4pos T cells has been reported in
blood and synovial fluid (22), while patients affected by systemic
lupus erythematosus (SLE) showed an increase in the percentage
of NKG2Dpos T cells and a decrease of NKG2D in NK cells in
terms of expression, percentage, and relative number (23–25).
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FIGURE 4 | Profile of markers of activation and inhibition. Dot plot visualization of the percentages of CD69 (A), NKG2A (B), CD16 (C), Nkp30 (D), and Nkp46 (E)
positive cells in NK, NKT and T lymphocyte gates determined by flow cytometry in PBMCs from BD patients ( ) and HC (). Horizontal lines show the median ± IQR.
Data were analyzed by Mann-Whitney U test.
Concerning Behçet disease, two studies identified a reduction
in the frequencies of NKG2Dpos cells in γδ T lymphocytes
and CD8bright CD56pos and CD8bright CD56neg lymphocytes
(26, 27), whereas an increased percentage of NKG2Dpos CD4pos
lymphocytes has been reported by Clemente et al. (28). In our
knowledge this is the first study that describes an increased
frequencies of circulating NKG2Dpos NK, NKT, and T cells.
We classified the lymphocytes widely, based on CD3 and
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FIGURE 5 | CD107a degranulation assay of PBMCs from BD patients and HC. Dot plot visualization of the percentages of CD107apos cells in the NK lymphocyte
gate determined by flow cytometry in PMBCs from BD patients ( ) and HC () after stimulation with K562 in presence of 10µg/mL brefeldin A and 6µg/mL
monensin. The assay was conducted without (A) or with 1ng/mL IL-15 (B) to maximize the stimulus. Horizontal lines show the median ± IQR. Data were analyzed by
Mann-Whitney U test.
CD56 expression thus comparing and integrating the results is
difficult. Here, we found that determining the frequencies of
circulating NKG2Dpos NK, NKT, and T cells could discriminate
between BD patients and HC with high degree of specificity,
but low sensitivity. The comparison with other inflammatory
diseases which need a differential diagnosis with BD is necessary
to confirm the diagnostic utility of testing the expression of
NKG2D. The BDCAF scores of BD patients correlated with
the frequencies of NKG2Dpos NK and NKT cells in peripheral
blood. Interestingly, BD patients with BDCAF = 0 had a
NKG2D profile similar to HC, while BD patients with BDCAF
≥ 3 had a higher frequency of NKG2Dpos NK, NKT, and T
cells. If NKG2D expression has a role in BD pathogenesis and
disease activity we might thus speculate that only patients with
BDCAF = 0 might be considered inactive/in remission. In line
to our findings, the percentages of NKG2Dpos lymphocytes have
been previously associated with disease activity in CD8bright
CD56pos, CD8bright CD56neg, and in CD4pos lymphocytes
(27, 28).
The comparison between patients with BD and healthy
subjects can especially provide knowledge on the pathogenesis
of the disease. As a result to the increased frequencies of
circulating NKG2Dpos NK and NKT cells, the immune system
of BD patients might be more prone to respond to ligands
of NKG2D when exposed to tissue cells (e.g., in case of cell
stress, infections, cell transformation) likely leading to recurrent
episodes of inflammation.
Recently, Hasan and collaborators reported an increase of
the cytotoxicity of NK cells in peripheral blood of BD patients
(15). They utilized the stimulus with phorbol-12-myristate-13-
acetate (PMA) and ionomycin to activate NK cells and the
cytotoxic potential of the cells was evaluated by monitoring the
frequency of NK cells positive for CD107a surface marker. Here,
we similarly evaluated the frequency of CD107apos NK cells
but following stimulation by the contact with cells missing the
MHC-I class molecules (K562 cells). In comparison to PMA and
ionomycin, it is a stimulus that better reflects the physiologic
activation of NK cells in the organism. Also in these experimental
conditions, the frequency of CD107apos NK cells was higher
in BD patients than HC. This difference mainly derived from
5 patients showing a higher frequency of CD107apos NK cells.
We cannot compare our results with those from Hasan and
collaborators because they depicted the degranulation assay
results as column graphs which do not allow to evaluate data
distribution.
All the cytokines, we found increased in plasma of BD
patients, are linked with NK and NKT activity based on literature
data. IL-5, IL-10, and IL-13 can be released from activated NK
and NKT cells (29, 30). IL-6 can play a role in the activation of
NK cells (31). MIP-1β, also known as CCL4, has a double role: to
one hand it acts as a NK cell chemoattractant signal produced by
dendritic cells; to the other hand it is produced by activated NK
cells (32). IP-10, also known as CXCL10, is produced by dendritic
cells and can attract NK cells in the sites of inflammation (32).
Increased levels of circulatingMIP-1β are reported here for the
first time. Differently from our findings, Aktas Cetin et al. did not
find any differences regarding the concentration of IL-5 between
BD patients and HC (33). According to our findings, increased
levels of CXCL10/IP-10 have been reported by Takeuchi et al. (34)
while no differences have been found by Lopalco et al. (35) and
Saruhan-Direskeneli et al. (36). Literature data regarding IL-10
levels in plasma and/or serum are indeed controversial. In one
study lower serum and plasma levels of IL-10 have been reported
in BD patients compared with HC (37). No differences have been
found in 4 studies (33, 38–40). IL-10 was not detected in serum
samples in two studies (41, 42). In line with our results, higher
levels of IL-10 have been reported in BD patients by Turan et al.
(43), Aridogan et al. (44) and Hamzaoui et al. (45). Concerning
IL-6, the involvement of this cytokine pathway in BD is well
documented and recently an antibody anti-IL6 receptor blocking
IL-6 activities has shown efficacy in the treatment of BD (46).
Interestingly, increased levels of circulating IL-13 in BD patients
have been reported in other 3 manuscripts suggesting that IL-13
might have a role in BD (44, 47, 48).
Finally, concerning IL-13 and MIP-1β, it is important to
highlight that the transcription of these factors is directly under
the control of NKG2D pathway (49). Therefore high levels of
IL-13 and MIP-1β found in plasma of BD patients might be
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FIGURE 6 | CD107a expression in lymphocytes of BD patients classified according to the BDCAF scores and therapy. (A) Dot plot visualization of the percentages of
CD107apos NK cells determined by flow cytometry in PBMCs from BD patients classified according to presence (N) or absence (◦) of therapy, after stimulation with
K562 in presence of 10µg/mL brefeldin A and 6µg/mL monensin. Horizontal lines show the median ± IQR. Data were analyzed by Mann-Whitney U test. (B) Dot plot
visualization of the correlation between the frequencies of CD107apos NK cells and BDCAF scores for each BD patient. Data were analyzed by Spearman’s correlation
test (n = 38). (C) Box plot visualization of the frequencies of CD107apos NK cells in BD patients with BDCAF = 0 vs. BDCAF ≥ 3 and HC. Data were analyzed by
Mann-Whitney U test.
downstream the increased activation of NKG2D pathway in NK,
NKT and T cells of BD patients compared to HC.
The limits of the present study concern the number of patients
and the fact that 74% of patients were under heterogeneous
therapies. However it has to be considered that Behçet is a rare
disease and our study is monocentric. In spite this limits, the
strong points of the study is that our cohort represents real life
patients thus the increased frequency of NKG2Dpos NK, NKT,
and T cells probably represents a pathogenic hit of BD.
Taken together, data here reported support the hypothesis that
through an increased frequency of NKG2D activatory receptor
on the cell surface, NK, NKT and T cells of BD patients could
be more prone to respond to NKG2D ligands when exposed
on tissue cells, leading to cyclic auto-inflammation. Concerning
the clinical practice, monitoring the frequencies of lymphocytes
expressing NKG2D could help the clinicians to identify BD
patients and/or to confirm disease activity during the follow-up.
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TABLE 1 | Levels of cytokines in plasma of BD patients and HC.
Concentration (pg/mL) Positive subjects (fraction)
BD
n= 38
HC
n= 20
Mann-Whitney
U test P value
BD
n = 38
HC
n = 20
Fisher’s test
P value
IL-1β 0.01 (0.01–4.73) 0.01 (0.01–0.01) 0.0701 16/38 4/20 0.1460
IL-1ra 53.83 (23.53–188.40) 32.29 (16.86–80.24) 0.0830 32/38 17/20 1
IL-2 0.01 (0.01–0.01) n.d. 0.2875 4/38 0/20 0.2875
IL-4 1.78 (0.01–3.55) 0.01 (0.01–0.01) 0.0385* 24/38 8/20 0.1055
IL-5 13.13 (4.55–29.49) 5.16 (0.01–17.04) 0.0193* 30/38 11/20 0.0734
IL-6 0.01 (0.01–13.43) 0.01 (0.01–0.01) 0.0180* 15/38 2/20 0.0318*
IL-7 3.20 (0.01–12.51) 0.01 (0.01–3.56) 0.0505 20/38 6/20 0.1643
IL-8 5.94 (0.01–15.68) 0.01 (0.01–7.19) 0.1895 25/38 11/20 0.5700
IL-9 13.66 (3.11–47.59) 8.75 (4.84–16.42) 0.3514 32/38 18/20 0.7015
IL-10 3.58 (0.01–26.73) 0.01 (0.01–0.01) 0.0107* 19/38 4/20 0.0467*
IL-12 (p70) 7.50 (0.01–27.64) 0.01 (0.01–13.63) 0.0624 20/38 6/20 0.1643
IL-13 8.13 (4.16–12.54) 2.79 (0.38–6.24) 0.0007*** 38/38 15/20 0.0034**
IL-15 0.01 (0.01–0.01) n.d. 0.3103 3/38 0/20 0.5443
IL-17A 8.74 (0.01–48.59) 0.01 (0.01–10.60) 0.0420* 23/38 7/20 0.0973
Eotaxin 67.73 (49.59–105.80) 65.53 (51.11–81.06) 0.4979 38/38 20/20 1
Basic FGF 32.02 (8.50–70.16) 28.40 (12.27–43.76) 0.5661 31/38 17/20 1
G-CSF 19.24 (9.22–61.32) 21.42 (9.51–27.81) 0.6876 32/38 18/20 0.7015
GM-CSF 31.63 (8.12–59.66) 70.10 (0.01–123.80) 0.2402 31/38 14/20 0.3387
IFN-γ 44.57 (0.01–171.6) 21.73 (0.01–54.92) 0.1801 26/38 13/20 0.7784
IP-10 573.40 (356.80–799.60) 319.00 (310.70–484.10) 0.0134* 38/38 20/20 1
MCP-1 0.01 (0.01–37.76) 0.01 (0.01–0.01) 0.0267* 18/38 4/20 0.0506
MIP-1α 3.62 (2.20–6.17) 2.70 (1.87–4.14) 0.1475 37/38 19/20 1
MIP-1β 40.62 (23.35–88.57) 27.25 (20.01–34.36) 0.0213* 38/38 20/20 1
PDGF-BB 104.90 (28.62–289.3) 75.69 (27.00–135.80) 0.4096 37/38 20/20 1
RANTES 1972 (1156–4954) 1467 (980.30–3138) 0.1930 38/38 20/20 1
TNF-α 21.57 (0.01–92.34) 12.88 (0.01–21.68) 0.0620 25/38 11/20 0.5700
VEGF 12.58 (0.01–32.93) 6.34 (0.01–17.41) 0.0810 28/38 11/20 0.2386
Cytokine concentrations are expressed in pg/ml as median (IQR). Data were analyzed by Mann-Whitney U test. Fractions represent the number of subjects in which the cytokines were
detectable. A cytokine was considered not detectable if its signal was lower than that of the least concentrated cytokine standard. Data were analyzed by Fisher’s exact test. n.d., not
detected; *P < 0.05; **P < 0.01; ***P < 0.001.
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